Michaela L. Tsai

1.9k total citations
35 papers, 850 citations indexed

About

Michaela L. Tsai is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michaela L. Tsai has authored 35 papers receiving a total of 850 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 13 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michaela L. Tsai's work include Breast Cancer Treatment Studies (10 papers), Advanced Breast Cancer Therapies (8 papers) and Cancer Treatment and Pharmacology (8 papers). Michaela L. Tsai is often cited by papers focused on Breast Cancer Treatment Studies (10 papers), Advanced Breast Cancer Therapies (8 papers) and Cancer Treatment and Pharmacology (8 papers). Michaela L. Tsai collaborates with scholars based in United States, France and United Kingdom. Michaela L. Tsai's co-authors include Karen K. Swenson, Mary Jo Nissen, Anne Blaes, Rajaram Gopalakrishnan, Vivek Thumbigere‐Math, Bryan S. Michalowicz, Tamera J. Lillemoe, Sami Diab, James S. Hodges and Sharon Wilks and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Michaela L. Tsai

35 papers receiving 833 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michaela L. Tsai United States	17	561	244	200	124	101	35	850
Annabel Goodwin Australia	18	722 1.3×	396 1.6×	330 1.6×	149 1.2×	256 2.5×	45	1.1k
Theodore A. Vandenberg Canada	12	463 0.8×	161 0.7×	110 0.6×	50 0.4×	206 2.0×	26	774
Sara López‐Tarruella Spain	19	672 1.2×	277 1.1×	240 1.2×	49 0.4×	228 2.3×	89	962
Johanna G. H. van Nes Netherlands	16	681 1.2×	349 1.4×	182 0.9×	160 1.3×	288 2.9×	31	1.2k
Hamdy A. Azim Egypt	19	766 1.4×	252 1.0×	352 1.8×	64 0.5×	230 2.3×	66	1.1k
Hans-Joachim Lueck Germany	14	532 0.9×	276 1.1×	238 1.2×	86 0.7×	81 0.8×	37	917
Sara Donati Italy	16	497 0.9×	220 0.9×	191 1.0×	57 0.5×	105 1.0×	40	756
Elena Verri Italy	17	711 1.3×	407 1.7×	551 2.8×	31 0.3×	324 3.2×	55	1.2k
A. Robinson United Kingdom	12	393 0.7×	332 1.4×	241 1.2×	62 0.5×	80 0.8×	35	764
Timothy P. Spiro United States	14	289 0.5×	161 0.7×	132 0.7×	122 1.0×	260 2.6×	32	700

Countries citing papers authored by Michaela L. Tsai

Since Specialization

Citations

This map shows the geographic impact of Michaela L. Tsai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michaela L. Tsai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michaela L. Tsai more than expected).

Fields of papers citing papers by Michaela L. Tsai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michaela L. Tsai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michaela L. Tsai. The network helps show where Michaela L. Tsai may publish in the future.

Co-authorship network of co-authors of Michaela L. Tsai

This figure shows the co-authorship network connecting the top 25 collaborators of Michaela L. Tsai. A scholar is included among the top collaborators of Michaela L. Tsai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michaela L. Tsai. Michaela L. Tsai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Edward S., Vamsidhar Velcheti, Tarek Mekhail, et al.. (2022). Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nature Medicine. 28(5). 939–945. 111 indexed citations

Allison, Kimberly H., David G. Hicks, Karen K. Swenson, et al.. (2021). HER2 Testing: Insights From Pathologists’ Perspective on Technically Challenging HER2 FISH Cases. Applied immunohistochemistry & molecular morphology. 29(9). 635–642. 2 indexed citations

Tolaney, Sara M., Kevin Kalinsky, Virginia Kaklamani, et al.. (2021). Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. Clinical Cancer Research. 27(11). 3061–3068. 90 indexed citations

Lillemoe, Tamera J., et al.. (2021). HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. International Journal of Breast Cancer. 2021. 1–11. 2 indexed citations

Robinson, Patricia A., Michaela L. Tsai, Shelly S. Lo, et al.. (2021). Genomic risk classification by the 70-gene signature and 21-gene assay in African American early-stage breast cancer patients.. Journal of Clinical Oncology. 39(15_suppl). e12568–e12568. 2 indexed citations

Zeidan, Amer M., Maya Ridinger, Tara L. Lin, et al.. (2020). A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clinical Cancer Research. 26(23). 6132–6140. 57 indexed citations

Han, Hyo S., Carlos Alemany, Ursa Brown‐Glaberman, et al.. (2019). SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer.. Journal of Clinical Oncology. 37(15_suppl). TPS1110–TPS1110. 26 indexed citations

Janni, Wolfgang, Emilio Alba, Thomas Bachelot, et al.. (2018). First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. Breast Cancer Research and Treatment. 169(3). 469–479. 35 indexed citations

Lillemoe, Tamera J., Michaela L. Tsai, Karen K. Swenson, et al.. (2018). Clinicopathologic analysis of a large series of microinvasive breast cancers. The Breast Journal. 24(4). 574–579. 15 indexed citations

10.

Schwartzberg, Lee S., Emilio Esteban, Dolores Isla, et al.. (2018). Clinical concordance study of a 17-gene liquid biopsy NGS panel for non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 36(15_suppl). e21065–e21065. 1 indexed citations

11.

Tsai, Michaela L., Shelly S. Lo, William Audeh, et al.. (2017). Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay. JAMA Oncology. 4(1). e173470–e173470. 32 indexed citations

12.

Barton, Debra L., Jeff A. Sloan, Lynne T. Shuster, et al.. (2017). Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Supportive Care in Cancer. 26(2). 643–650. 54 indexed citations

13.

Anders, Carey K., Rashmi K. Murthy, Erika Hamilton, et al.. (2017). A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs. placebo in combination with capecitabine (C) and trastuzumab (Tz) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB).. Journal of Clinical Oncology. 35(15_suppl). TPS1107–TPS1107. 1 indexed citations

14.

Goy, André, Andres Forero, Nina D. Wagner‐Johnston, et al.. (2016). A phase 2 study of inotuzumab ozogamicin in patients with indolent B‐cell non‐Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. British Journal of Haematology. 174(4). 571–581. 40 indexed citations

15.

Tsai, Michaela L., et al.. (2016). The 70-gene signature to provide risk stratification and treatment guidance for patients classified as intermediate by the 21-gene assay.. Journal of Clinical Oncology. 34(15_suppl). 571–571. 3 indexed citations

16.

Tsai, Michaela L., et al.. (2014). Utility of Oncotype DX risk assessment in patients with invasive lobular carcinoma (ILC).. Journal of Clinical Oncology. 32(26_suppl). 28–28. 1 indexed citations

17.

Swenson, Karen K., et al.. (2013). Identification of Tools to Measure Changes in Musculoskeletal Symptoms and Physical Functioning in Women With Breast Cancer Receiving Aromatase Inhibitors. Oncology nursing forum. 40(6). 549–557. 23 indexed citations

18.

Swenson, Karen K., et al.. (2013). Cancer Rehabilitation. Cancer Nursing. 37(3). 162–169. 10 indexed citations

19.

Nissen, Mary Jo, et al.. (2013). Effectiveness of treatment summaries in increasing breast and colorectal cancer survivors’ knowledge about their diagnosis and treatment. Journal of Cancer Survivorship. 7(2). 211–218. 35 indexed citations

20.

Nissen, Mary Jo, Michaela L. Tsai, Anne Blaes, & Karen K. Swenson. (2011). Breast and colorectal cancer survivors’ knowledge about their diagnosis and treatment. Journal of Cancer Survivorship. 6(1). 20–32. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact